Modified Citrus Pectin – Peeling Back the Science on Surprising Trial Results!

In this episode of The Moss Report, Ben Moss speaks with Dr. Ralph Moss about a little-known natural compound that may have big implications: Modified Citrus Pectin (MCP). A recent clinical trial in Israel found that MCP helped slow PSA doubling time in men with recurrent prostate cancer—suggesting it may offer real, measurable support for patients after treatment. Ben and Ralph trace the story from its origins in the 1990s through modern-day research, digging into how MCP works by targeting Galectin-3, a molecule tied to inflammation and cancer spread. Along the way, they highlight the researchers who kept this idea alive, including Dr. Kenneth Pienta and Dr. Isaac Eliaz, and ask why this research isn't more widely known. It's an honest, science-based conversation about where evidence and action meet—and how natural approaches might still be flying under the radar. Link to the full article with transcript, slide presentation, links and cited studies. https://www.themossreport.com/mcp-podcast/ Products mentioned in this podcast: Pectasol-C – https://econugenics.com/?a_aid=TMR Mycolife – The Moss Method Mushroom Formula – https://mycolife.us/product/the-moss-method-mushroom-formula/ Links and Resources: 🌿 The Moss Method – Fight Cancer Naturally – (Paperback, Hardcover, Kindle) https://www.amazon.com/gp/product/1881025799/ 📘 The Moss Report Cancer Treatment Guides – https://themossreport.store/guides 📚 Dr. Moss' Full Catalog of Books on Cancer – https://themossreport.store/books/ 🌎 Full Transcript, Research Notes, Articles & Videos – https://www.themossreport.com 🤝 The Moss Report is sponsored by Mycolife.US - Makers of The World's Best Mushroom Extracts, including The Moss Method Mushroom Formula, available exclusively at https://www.mycolife.us/ National Center for Complementary and Integrative Health - https://www.nccih.nih.gov/ Studies relating to Modified Citrus Pectin: Conti S, Vexler A, Hagoel L, Kalich-Philosoph L, Corn BW, Honig N, Shtraus N, Meir Y, Ron I, Eliaz I, Lev-Ari S. Modified Citrus Pectin as a Potential Sensitizer for Radiotherapy in Prostate Cancer. Integr Cancer Ther. 2018 Dec;17(4):1225-1234. doi: 10.1177/1534735418790382. Epub 2018 Jul 25. PMID: 30043669; PMCID: PMC6247563.  https://pubmed.ncbi.nlm.nih.gov/30043669/ Guess BW, Scholz MC, Strum SB, et al. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer Prostatic Dis. 2003;6(4):301-4. doi: 10.1038/sj.pcan.4500679. PMID: 14663471. https://pubmed.ncbi.nlm.nih.gov/14663471/ Inohara H, Raz A. Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconj J. 1994 Dec;11(6):527-32. doi: 10.1007/BF00731303. PMID: 7696855. https://pubmed.ncbi.nlm.nih.gov/7696855/ IInufusa H, Nakamura M, Adachi T, et al.. Role of galectin-3 in adenocarcinoma liver metastasis. Int J Oncol. 2001 Nov;19(5):913-9. doi: 10.3892/ijo.19.5.913. PMID: 11604988. https://pubmed.ncbi.nlm.nih.gov/11604988/ Keizman D, Frenkel M, Peer A, et al.. Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study. Nutrients. 2021 Nov 28;13(12):4295. doi: 10.3390/nu13124295. PMID: 34959847; PMCID: PMC8706421. https://pmc.ncbi.nlm.nih.gov/articles/PMC8706421/ Keizman D, Frenkel M, Peer A, et al. Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study. Nutrients. 2023 Aug 11;15(16):3533. doi: 10.3390/nu15163533. PMID: 37630724; PMCID: PMC10459199.  https://pmc.ncbi.nlm.nih.gov/articles/PMC10459199/ Nakamura M, Inufusa H, Adachi T et al. Involvement of galectin-3 expression in colorectal cancer progression and metastasis. Int J Oncol 1999; 15(1):143-148. https://pubmed.ncbi.nlm.nih.gov/10375607/ Nangia-Makker P, Hogan V, Honjo Y, et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst. 2002 Dec 18;94(24):1854-62. doi: 10.1093/jnci/94.24.1854. PMID: 12488479. https://pubmed.ncbi.nlm.nih.gov/12488479/ Pienta KJ, Naik H, Akhtar A, Yamazaki K, Replogle TS, Lehr J, Donat TL, Tait L, Hogan V, Raz A. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst. 1995 Mar 1;87(5):348-53. doi: 10.1093/jnci/87.5.348. PMID: 7853416. https://pubmed.ncbi.nlm.nih.gov/7853416/